Company news

Paradigm Biopharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Paradigm Receives $7.4m R&D Tax Incentive Refund

November 18, 2022

Paradigm Doses First UK Participant in Phase 3 Trial

October 25, 2022

PAR Reports Successful Primary Endpoint in Phase 2 Trial

October 3, 2022

Successful MPSVI Safety Review and PARA OA 008 Update

September 25, 2022

Successful Completion of Entitlement Offer

September 12, 2022

2022 Annual Report and Appendix 4E

August 25, 2022

PAR Non-Renounceable Rights Issue Offer Booklet

August 21, 2022

Investor Presentation - $66m Capital Raise

August 14, 2022

Paradigm Launches $66M Capital Raising

August 14, 2022

Paradigm provides MPS Clinical Program update

August 7, 2022

Quarterly Update and Appendix 4C - quarterly

July 27, 2022

Paradigm Partners with NFL Alumni Health for OA Program

July 13, 2022

Paradigm reports global progress in phase 3 study

July 5, 2022

100% Recruitment in Synovial Fluid Biomarker Trial

June 30, 2022

Paradigm Reports Australian Patent Acceptance

June 29, 2022

Paradigm Receives $8.2m R&D Tax Incentive Refund

June 6, 2022

Paradigm Appoints Experienced US-Based CEO

May 29, 2022

Paradigm Doses First US Subjects under Phase 3 trial

April 28, 2022

FDA Grants Paradigm Fast Track Designation For OA

April 12, 2022

Clarification of recent analyst report on Patent Protection

March 9, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

Paradigm 1HY22 Key Activity Highlights

February 23, 2022

Paradigm treats first subjects in phase 3 trial of Zilosul

January 12, 2022

PAR reports postive topline results in heart failure model

December 16, 2021

Preliminary Results from Phase 2 MPS I Study

November 22, 2021

Paradigm CEO Paul Rennie to transition to Non-Exec Chairman

November 21, 2021

Paradigm cleared for phase 3 trial by US FDA

November 2, 2021

Phase 2 Synovial Fluid Biomarker Study Update

October 25, 2021

Positive top-line results from preclinical study in ARDS

October 12, 2021

First mps-vi patient dosed under phase 2 trial in Brazil

September 30, 2021

Paradigm receives feedback from US FDA on ind submission

September 26, 2021

Aus ethics approval received for Phase 3 trial

September 23, 2021

2021 Annual Report and Appendix 4E

August 26, 2021

Paradigm reports ind application update

August 2, 2021

Paradigm submits responses to US FDA questions

June 29, 2021

Paradigm receives key regulatory approvals for mps vi study

June 17, 2021

IND questions received from US FDA

May 24, 2021

Paradigm achieves first revenue

May 18, 2021

Paradigm provides ind application update

April 25, 2021

Paradigm doses first participant in Synovial Fluid Trial

April 13, 2021

Paradigm and Bene Execute New Collaboration Agreement

March 30, 2021

Paradigm delivers IND to US FDA for Pivotal OA Program

March 25, 2021

Consistent pain reduction and improvement in function data

February 2, 2021

Response to ASX Query

January 21, 2021

R&D Investor Presentation

December 20, 2020

Paradigm receives postive feedback from FDA type c meeting

December 17, 2020

Paradigm Provides Phase 3 Clinical Trial Update

December 13, 2020

First patient dosed in mps-i phase 2 clinical trial

November 11, 2020

Zilosul reduces pain in patients with knee oa

September 30, 2020

Extension of exclusive agreement with bene pharmaChem

September 28, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 30 decks. Every deck is listed under its year.